Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buntanetap + dulaglutide
- Development stage
- Unknown
- Lead developer
- Annovis Bio
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
buntanetap + dulaglutide is an investigational combination therapy being developed by Annovis Bio for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Buntanetap is an orally available small molecule that inhibits the translation of neurotoxic proteins such as amyloid precursor protein (APP), tau, and alpha-synuclein, thereby reducing neuroinflammation and improving synaptic function. Dulaglutide (Trulicity) is a glucagon-like peptide 1 (GLP-1) receptor agonist traditionally used for type 2 diabetes, which has shown neuroprotective effects in preclinical models. Preclinical data suggest that the combination of buntanetap and dulaglutide may have synergistic effects, potentially restoring or even enhancing cognitive function beyond healthy control levels.
- Brand names
- Trulicity
- Other names
- buntanetap + Trulicity
02
Targets
IRE (Iron-responsive element (IRE) sequences in mRNA of neurotoxic proteins)GLP1R (GLP-1R)
Beyond the preview
Go deeper on buntanetap + dulaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buntanetap + dulaglutide.